Free Trial
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

Fortress Biotech logo
$1.91 +0.03 (+1.60%)
As of 04:00 PM Eastern

About Fortress Biotech Stock (NASDAQ:FBIO)

Key Stats

Today's Range
$1.85
$2.05
50-Day Range
$1.65
$2.13
52-Week Range
$1.33
$2.89
Volume
631,248 shs
Average Volume
413,142 shs
Market Capitalization
$56.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Fortress Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

FBIO MarketRank™: 

Fortress Biotech scored higher than 42% of companies evaluated by MarketBeat, and ranked 615th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fortress Biotech has received no research coverage in the past 90 days.

  • Read more about Fortress Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortress Biotech is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortress Biotech is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Fortress Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fortress Biotech does not currently pay a dividend.

  • Dividend Growth

    Fortress Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Search Interest

    7 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fortress Biotech's insider trading history.
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

FBIO Fortress Biotech, Inc. - Seeking Alpha
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

FBIO Stock Analysis - Frequently Asked Questions

Fortress Biotech's stock was trading at $2.03 at the start of the year. Since then, FBIO stock has decreased by 5.9% and is now trading at $1.91.

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings data on Monday, March, 31st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.53. The biopharmaceutical company had revenue of $15.12 million for the quarter, compared to the consensus estimate of $16.30 million. Fortress Biotech had a negative net margin of 71.24% and a negative trailing twelve-month return on equity of 4,712.53%.
Read the conference call transcript
.

Fortress Biotech's stock reverse split on Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

Last Earnings
3/31/2025
Today
7/07/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$26.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+999.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46 million
Pretax Margin
-183.81%

Debt

Sales & Book Value

Annual Sales
$57.67 million
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-31.83

Miscellaneous

Free Float
21,320,000
Market Cap
$56.48 million
Optionable
Optionable
Beta
1.75

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:FBIO) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners